Celyad Oncology S.A. | Small-cap | Healthcare
€0.39
0.00%
| Celyad Oncology S.A Stock Comparison:
Celyad Oncology S.A vs Argenx SECelyad Oncology S.A vs UCB S.ACelyad Oncology S.A vs European MedicalCelyad Oncology S.A vs Biosenic SACelyad Oncology S.A vs Oxurion NVCelyad Oncology S.A vs BEL 20 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2022

Income Metrics

Revenue 0
Gross Profit 0
Operating Income -7.6M
Net Income -6.5M
EPS (Diluted) €-0.28

Balance Sheet Metrics

Total Assets 12.2M
Total Liabilities 11.2M
Shareholders Equity 1.0M
Debt to Equity 10.95

Cash Flow Metrics

Revenue & Profitability Trend

Celyad Oncology S.A Income Statement From 2018 to 2022

Metric20222021202020192018
Revenue i005.0K6.0K3.1M
Cost of Goods Sold i00000
Gross Profit i005.0K6.0K3.1M
Gross Margin % i0.0%0.0%100.0%100.0%100.0%
Operating Expenses
Research & Development i18.9M20.8M21.5M25.2M24.9M
Selling, General & Administrative i10.3M9.7M9.3M8.7M10.1M
Other Operating Expenses i-8.7M-3.1M-4.6M-3.4M-525.0K
Total Operating Expenses i20.5M27.4M26.2M30.6M34.5M
Operating Income i-20.3M-26.9M-26.2M-29.4M-31.4M
Operating Margin % i0.0%0.0%-524,300.0%-489,550.0%-1,007.6%
Non-Operating Items
Interest Income i12.0K27.0K217.0K582.0K804.0K
Interest Expense i197.0K255.0K434.0K343.0K62.0K
Other Non-Operating Income-20.4M523.0K9.2M495.0K-6.8M
Pre-tax Income i-40.9M-26.5M-17.2M-28.6M-37.4M
Income Tax i65.0K10.0K0-8.0K0
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-40.9M-26.5M-17.2M-28.6M-37.4M
Net Margin % i0.0%0.0%-344,080.0%-477,200.0%-1,201.5%
Key Metrics
EBITDA i-18.8M-25.6M-24.2M-27.1M-30.5M
EPS (Basic) i€-1.81€-1.70€-1.23€-2.29€-3.36
EPS (Diluted) i€-1.81€-1.70€-1.23€-2.29€-3.36
Basic Shares Outstanding i2259395615604014139423441252316611138988
Diluted Shares Outstanding i2259395615604014139423441252316611138988

Income Statement Trend

Celyad Oncology S.A Balance Sheet From 2018 to 2022

Metric20222021202020192018
Assets
Current Assets
Cash & Equivalents i12.4M30.0M17.2M39.3M40.5M
Short-term Investments i00009.2M
Accounts Receivable i909.0K203.0K165.0K156.0K277.0K
Inventory i-----
Other Current Assets--1.0K-1.0K
Total Current Assets i14.8M34.3M19.7M42.8M51.7M
Non-Current Assets
Property, Plant & Equipment i1.3M6.8M6.6M6.9M3.9M
Goodwill i864.0K37.1M37.1M37.1M37.0M
Intangible Assets i864.0K35.3M35.3M35.3M35.3M
Long-term Investments-----
Other Non-Current Assets3.5M6.0M5.8M5.5M3.2M
Total Non-Current Assets i4.9M45.7M46.4M47.0M42.6M
Total Assets i19.7M79.9M66.1M89.8M94.3M
Liabilities
Current Liabilities
Accounts Payable i4.8M6.6M4.7M7.0M5.9M
Short-term Debt i137.0K902.0K1.1M1.4M765.0K
Current Portion of Long-term Debt-----
Other Current Liabilities710.0K2.3M1.3M350.0K1.0M
Total Current Liabilities i10.4M13.8M11.8M11.9M9.6M
Non-Current Liabilities
Long-term Debt i118.0K1.7M2.5M3.0M881.0K
Deferred Tax Liabilities i-----
Other Non-Current Liabilities258.0K164.0K371.0K-25.2M
Total Non-Current Liabilities i5.0M22.5M23.3M32.3M29.1M
Total Liabilities i15.4M36.3M35.1M44.2M38.7M
Equity
Common Stock i78.6M78.6M48.5M48.5M41.6M
Retained Earnings i-349.9M-309.0M-283.0M-74.4M-217.8M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i4.3M43.6M31.0M45.6M55.6M
Key Metrics
Total Debt i255.0K2.6M3.6M4.4M1.6M
Working Capital i4.4M20.5M7.9M30.9M42.0M

Balance Sheet Composition

Celyad Oncology S.A Cash Flow Statement From 2018 to 2022

Metric20222021202020192018
Operating Activities
Net Income i-40.9M-26.5M-17.2M-28.6M-37.4M
Depreciation & Amortization i1.4M1.5M1.8M1.8M1.1M
Stock-Based Compensation i1.6M2.2M2.8M2.8M3.6M
Working Capital Changes i-4.0M1.4M-2.9M-610.0K-978.0K
Operating Cash Flow i-60.2M-26.1M-28.7M-28.3M-28.7M
Investing Activities
Capital Expenditures i112.0K-64.0K326.0K-187.0K-759.0K
Acquisitions i6.0M0000
Investment Purchases i--00-26.6M
Investment Sales i1.1M009.4M28.9M
Investing Cash Flow i7.2M-64.0K326.0K9.2M1.5M
Financing Activities
Share Repurchases i-124.0K----
Dividends Paid i-----
Debt Issuance i--00950.0K
Debt Repayment i-896.0K-1.1M-1.4M-1.5M-749.0K
Financing Cash Flow i3.2M39.5M5.4M18.3M43.9M
Free Cash Flow i-28.1M-27.0M-28.0M-28.8M-29.0M
Net Change in Cash i-49.8M13.3M-23.0M-819.0K16.8M

Cash Flow Trend

Celyad Oncology S.A Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -0.22
Forward P/E 0.61
Price to Book 32.50
Price to Sales 86.87
PEG Ratio 0.61

Profitability Ratios

Profit Margin 0.00%
Operating Margin -1,619.77%
Return on Equity -170.92%
Return on Assets -28.00%

Financial Health

Current Ratio 2.29
Debt to Equity 177.10
Beta 1.05

Per Share Data

EPS (TTM) €-1.36
Book Value per Share €0.01
Revenue per Share €0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
cyad16.2M-0.2232.50-170.92%0.00%177.10
Argenx SE 36.2B33.975.7824.72%41.03%0.71
UCB S.A 35.1B26.923.6214.30%19.45%29.72
European Medical 19.5M35.381.885.40%1.14%191.98
Biosenic SA 1.6M0.00-126.75%-279.17%-1.18
Oxurion NV 1.5M0.00--1.08%3,966.67%-1.02

Financial data is updated regularly. All figures are in the company's reporting currency.